Market news

Detailed price information for Lennox International (LII-N) from The Globe and Mail including charting and trades.

Bio-Techne Corporation (NASDAQ:TECH) shareholders voted on September 23 to approve the company’s acquisition by Merck KGaA of Darmstadt, Germany. The German group is paying $73 a share in cash, valuing the business at about $11.3 billion including debt. They also voted down the executive compensation proposal attached to the deal, which is an unusual pairing. […]

Robert V Baumgartner, Board Member at Bio-Techne (NASDAQ:TECH), reported a large exercise of company stock options on September 24, according to a new SEC filing. What Happened: In an insider options exercise disclosed

Bio-Techne has outperformed the Nasdaq over the past year, but analysts are cautious about the stock’s prospects.

Merck KGaA (XTRA:MRK) has received shareholder approval from Bio-Techne investors for its planned acquisition of the US life sciences group. The vote clears a major corporate hurdle in the transaction process, with completion still subject to remaining regulatory reviews. The planned merger is expected to broaden the combined product set and customer reach across multiple stages of the life sciences workflow. The Bio-Techne shareholder approval is important, but it should not be the only...

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the opening of its new Customer Experience Center in Düsseldorf, Germany, a flagship facility designed to bring European customers closer to Bio-Techne's latest innovations and scientific expertise.

Bio-Techne (TECH) has drawn fresh attention after recent trading left the share price at $72.27, with performance over the past month roughly flat and the past 3 months showing a strong double digit gain. Recent trading tells a mixed story for Bio-Techne. The share price return of 29% over the past 90 days sits alongside a 1-year total shareholder return of 41%, while the 5-year total shareholder return shows a decline of 44%. This hints that momentum has only recently improved following a...

Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

500-Page Report Spans 450 Data Tables Across Product, Species, Host Cell, and Application Segments as Human Recombinant Proteins Lead Demand Research Use Recombinant Protein Market Research Use Recombinant Protein Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Research Use Recombinant Protein Market by Product, Product Formulation, Species, Host Cell, Application, End User, Region - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. Research Use Recombinant Pro

500-Page Report Ranks Suppliers by Competitive Position Across the Company Evaluation Matrix as Infectious Disease Testing Drives the Largest Application Segment IVD Raw Material Market IVD Raw Material Market Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "IVD Raw Material Market by Product Type, Technology, Application, Supply Source, Origin, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering. The global in vitro diagnostics (IVD) raw material market is pro

Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced significant progress toward its climate and sustainability objectives, including validation of its greenhouse gas reduction targets by the Science Based Targets initiative (SBTi) and substantial reductions in operational emissions during fiscal year 2026.

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the research tools & consumables stocks, including Bio-Techne (NASDAQ:TECH) and its peers.

Bio-Techne has outperformed the broader market over the past year, but analysts are cautious about the stock’s prospects.

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Bio-Techne (TECH) has an average rating of hold and mean price target of $70.09, according to analys

Bio-Techne Corporation (NASDAQ: TECH) is issuing a correction to its dividend announcement released yesterday. The initial version incorrectly stated the shareholder of record date as August 17, 2026. The correct shareholder of record date is August 24, 2026. All other information contained in the dividend announcement remains unchanged.

Techne (TECH) delivered earnings and revenue surprises of 0.00% and +1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the fourth quarter ending June 30, 2026.

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ consensus estimates.

Aug 12 () - Bio-Techne beat Wall Street estimates for fourth-quarter revenue ‌on Wednesday helped by growth ‌in its research and diagnostics businesses. Here are some ​details: • Bio-Techne is in the process of being acquired by Germany's Merck KGaA in a deal valued at ‌about $11.

Bio-Techne (TECH) reported fiscal Q4 adjusted earnings Wednesday of $0.52 per diluted share, down fr

TECH heads into fiscal fourth-quarter earnings with revenues expected to remain flat, EPS projected to decline, and its $11.3 billion acquisition deal in focus.

Bio-Techne is scheduled to post its fourth-quarter results soon, and analysts project a single-digit earnings decline.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.